Cargando…

PAR-4/Ca(2+)-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes

BACKGROUND: Patients with type 2 diabetes (T2DM) have a prothrombotic state that needs to be fully clarified; microparticles (MPs) have emerged as mediators and markers of this condition. Thus, we investigate, in vivo, in T2DM either with good (HbA1c ≤ 7.0%; GGC) or poor (HbA1c > 7.0%; PGC) glyce...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannella, Alessandra, Ceolotto, Giulio, Radu, Claudia Maria, Cattelan, Arianna, Iori, Elisabetta, Benetti, Andrea, Fabris, Fabrizio, Simioni, Paolo, Avogaro, Angelo, Vigili de Kreutzenberg, Saula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019350/
https://www.ncbi.nlm.nih.gov/pubmed/33812377
http://dx.doi.org/10.1186/s12933-021-01267-w
_version_ 1783674360817516544
author Giannella, Alessandra
Ceolotto, Giulio
Radu, Claudia Maria
Cattelan, Arianna
Iori, Elisabetta
Benetti, Andrea
Fabris, Fabrizio
Simioni, Paolo
Avogaro, Angelo
Vigili de Kreutzenberg, Saula
author_facet Giannella, Alessandra
Ceolotto, Giulio
Radu, Claudia Maria
Cattelan, Arianna
Iori, Elisabetta
Benetti, Andrea
Fabris, Fabrizio
Simioni, Paolo
Avogaro, Angelo
Vigili de Kreutzenberg, Saula
author_sort Giannella, Alessandra
collection PubMed
description BACKGROUND: Patients with type 2 diabetes (T2DM) have a prothrombotic state that needs to be fully clarified; microparticles (MPs) have emerged as mediators and markers of this condition. Thus, we investigate, in vivo, in T2DM either with good (HbA1c ≤ 7.0%; GGC) or poor (HbA1c > 7.0%; PGC) glycemic control, the circulating levels of MPs, and in vitro, the molecular pathways involved in the release of MPs from platelets (PMP) and tested their pro-inflammatory effects on THP-1 transformed macrophages. METHODS: In 59 T2DM, and 23 control subjects with normal glucose tolerance (NGT), circulating levels of CD62E+, CD62P+, CD142+, CD45+ MPs were determined by flow cytometry, while plasma levels of ICAM-1, VCAM-1, IL-6 by ELISA. In vitro, PMP release and activation of isolated platelets from GGC and PGC were investigated, along with their effect on IL-6 secretion in THP-1 transformed macrophages. RESULTS: We found that MPs CD62P(+) (PMP) and CD142(+) (tissue factor-bearing MP) were significantly higher in PGC T2DM than GGC T2DM and NGT. Among MPs, PMP were also correlated with HbA1c and IL-6. In vitro, we showed that acute thrombin exposure stimulated a significantly higher PMP release in PGC T2DM than GGC T2DM through a more robust activation of PAR-4 receptor than PAR-1 receptor. Treatment with PAR-4 agonist induced an increased release of PMP in PGC with a Ca(2+)-calpain dependent mechanism since this effect was blunted by calpain inhibitor. Finally, the uptake of PMP derived from PAR-4 treated PGC platelets into THP-1 transformed macrophages promoted a marked increase of IL-6 release compared to PMP derived from GGC through the activation of the NF-kB pathway. CONCLUSIONS: These results identify PAR-4 as a mediator of platelet activation, microparticle release, and inflammation, in poorly controlled T2DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01267-w.
format Online
Article
Text
id pubmed-8019350
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80193502021-04-05 PAR-4/Ca(2+)-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes Giannella, Alessandra Ceolotto, Giulio Radu, Claudia Maria Cattelan, Arianna Iori, Elisabetta Benetti, Andrea Fabris, Fabrizio Simioni, Paolo Avogaro, Angelo Vigili de Kreutzenberg, Saula Cardiovasc Diabetol Original Investigation BACKGROUND: Patients with type 2 diabetes (T2DM) have a prothrombotic state that needs to be fully clarified; microparticles (MPs) have emerged as mediators and markers of this condition. Thus, we investigate, in vivo, in T2DM either with good (HbA1c ≤ 7.0%; GGC) or poor (HbA1c > 7.0%; PGC) glycemic control, the circulating levels of MPs, and in vitro, the molecular pathways involved in the release of MPs from platelets (PMP) and tested their pro-inflammatory effects on THP-1 transformed macrophages. METHODS: In 59 T2DM, and 23 control subjects with normal glucose tolerance (NGT), circulating levels of CD62E+, CD62P+, CD142+, CD45+ MPs were determined by flow cytometry, while plasma levels of ICAM-1, VCAM-1, IL-6 by ELISA. In vitro, PMP release and activation of isolated platelets from GGC and PGC were investigated, along with their effect on IL-6 secretion in THP-1 transformed macrophages. RESULTS: We found that MPs CD62P(+) (PMP) and CD142(+) (tissue factor-bearing MP) were significantly higher in PGC T2DM than GGC T2DM and NGT. Among MPs, PMP were also correlated with HbA1c and IL-6. In vitro, we showed that acute thrombin exposure stimulated a significantly higher PMP release in PGC T2DM than GGC T2DM through a more robust activation of PAR-4 receptor than PAR-1 receptor. Treatment with PAR-4 agonist induced an increased release of PMP in PGC with a Ca(2+)-calpain dependent mechanism since this effect was blunted by calpain inhibitor. Finally, the uptake of PMP derived from PAR-4 treated PGC platelets into THP-1 transformed macrophages promoted a marked increase of IL-6 release compared to PMP derived from GGC through the activation of the NF-kB pathway. CONCLUSIONS: These results identify PAR-4 as a mediator of platelet activation, microparticle release, and inflammation, in poorly controlled T2DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01267-w. BioMed Central 2021-04-03 /pmc/articles/PMC8019350/ /pubmed/33812377 http://dx.doi.org/10.1186/s12933-021-01267-w Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Giannella, Alessandra
Ceolotto, Giulio
Radu, Claudia Maria
Cattelan, Arianna
Iori, Elisabetta
Benetti, Andrea
Fabris, Fabrizio
Simioni, Paolo
Avogaro, Angelo
Vigili de Kreutzenberg, Saula
PAR-4/Ca(2+)-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes
title PAR-4/Ca(2+)-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes
title_full PAR-4/Ca(2+)-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes
title_fullStr PAR-4/Ca(2+)-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes
title_full_unstemmed PAR-4/Ca(2+)-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes
title_short PAR-4/Ca(2+)-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes
title_sort par-4/ca(2+)-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019350/
https://www.ncbi.nlm.nih.gov/pubmed/33812377
http://dx.doi.org/10.1186/s12933-021-01267-w
work_keys_str_mv AT giannellaalessandra par4ca2calpainpathwayactivationstimulatesplateletderivedmicroparticlesinhyperglycemictype2diabetes
AT ceolottogiulio par4ca2calpainpathwayactivationstimulatesplateletderivedmicroparticlesinhyperglycemictype2diabetes
AT raduclaudiamaria par4ca2calpainpathwayactivationstimulatesplateletderivedmicroparticlesinhyperglycemictype2diabetes
AT cattelanarianna par4ca2calpainpathwayactivationstimulatesplateletderivedmicroparticlesinhyperglycemictype2diabetes
AT iorielisabetta par4ca2calpainpathwayactivationstimulatesplateletderivedmicroparticlesinhyperglycemictype2diabetes
AT benettiandrea par4ca2calpainpathwayactivationstimulatesplateletderivedmicroparticlesinhyperglycemictype2diabetes
AT fabrisfabrizio par4ca2calpainpathwayactivationstimulatesplateletderivedmicroparticlesinhyperglycemictype2diabetes
AT simionipaolo par4ca2calpainpathwayactivationstimulatesplateletderivedmicroparticlesinhyperglycemictype2diabetes
AT avogaroangelo par4ca2calpainpathwayactivationstimulatesplateletderivedmicroparticlesinhyperglycemictype2diabetes
AT vigilidekreutzenbergsaula par4ca2calpainpathwayactivationstimulatesplateletderivedmicroparticlesinhyperglycemictype2diabetes